465 related articles for article (PubMed ID: 24787454)
21. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.
Biswas S; Hwang JW; Kirkham PA; Rahman I
Curr Med Chem; 2013; 20(12):1496-530. PubMed ID: 22963552
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
23. Antioxidant therapeutic targets in COPD.
Rahman I; Kilty I
Curr Drug Targets; 2006 Jun; 7(6):707-20. PubMed ID: 16787173
[TBL] [Abstract][Full Text] [Related]
24. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review.
Sadowska AM; Manuel-Y-Keenoy B; De Backer WA
Pulm Pharmacol Ther; 2007; 20(1):9-22. PubMed ID: 16458553
[TBL] [Abstract][Full Text] [Related]
25. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
[TBL] [Abstract][Full Text] [Related]
26. [The application of N-acetylcysteine in optimization of specific pharmacological therapies].
Hołyńska-Iwan I; Wróblewski M; Olszewska-Słonina D; Tyrakowski T
Pol Merkur Lekarski; 2017 Sep; 43(255):140-144. PubMed ID: 28987048
[TBL] [Abstract][Full Text] [Related]
27. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
28. Oral
Hirai DM; Jones JH; Zelt JT; da Silva ML; Bentley RF; Edgett BA; Gurd BJ; Tschakovsky ME; O'Donnell DE; Neder JA
J Appl Physiol (1985); 2017 May; 122(5):1351-1361. PubMed ID: 28255088
[TBL] [Abstract][Full Text] [Related]
29. Role of oxidative stress in the pathogenesis of COPD.
Nucera F; Mumby S; Paudel KR; Dharwal V; DI Stefano A; Casolaro V; Hansbro PM; Adcock IM; Caramori G
Minerva Med; 2022 Jun; 113(3):370-404. PubMed ID: 35142479
[TBL] [Abstract][Full Text] [Related]
30. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
[TBL] [Abstract][Full Text] [Related]
31. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee.
Decramer M; Dekhuijzen PN; Troosters T; van Herwaarden C; Rutten-van Mölken M; van Schayck CP; Olivieri D; Lankhorst I; Ardia A
Eur Respir J; 2001 Mar; 17(3):329-36. PubMed ID: 11405507
[TBL] [Abstract][Full Text] [Related]
32. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
33. Antioxidant therapies in COPD.
Rahman I
Int J Chron Obstruct Pulmon Dis; 2006; 1(1):15-29. PubMed ID: 18046899
[TBL] [Abstract][Full Text] [Related]
34. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress.
Raghu G; Berk M; Campochiaro PA; Jaeschke H; Marenzi G; Richeldi L; Wen FQ; Nicoletti F; Calverley PMA
Curr Neuropharmacol; 2021; 19(8):1202-1224. PubMed ID: 33380301
[TBL] [Abstract][Full Text] [Related]
35. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
Blasi F; Page C; Rossolini GM; Pallecchi L; Matera MG; Rogliani P; Cazzola M
Respir Med; 2016 Aug; 117():190-7. PubMed ID: 27492531
[TBL] [Abstract][Full Text] [Related]
36. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen Y; Cai W; Lei S; Zhang Z
COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
[TBL] [Abstract][Full Text] [Related]
37. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
38. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M; Calzetta L; Page C; Jardim J; Chuchalin AG; Rogliani P; Matera MG
Eur Respir Rev; 2015 Sep; 24(137):451-61. PubMed ID: 26324807
[TBL] [Abstract][Full Text] [Related]
39. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
40. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]